Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.50 |
| ▸ | NPC1 | O15118 | 7/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | CASP3 | P42574 | 1/20 | 0.50 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.50 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.50 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 5/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3355680 | 0.84 | GRM4 (0.38) | RAB9ANPC1KMT2AMEN1ALDH1A1 | |
| SCHEMBL3356660 | 0.81 | RAB9A (0.56) | RAB9ANPC1KMT2AMEN1CASP3 | |
| SCHEMBL2210735 | 0.68 | NPC1 (1.00) | RAB9ANPC1KMT2AMEN1CASP3 | |
| SCHEMBL3358623 | 0.68 | NPC1 (0.68) | RAB9ANPC1KMT2AMEN1CASP3 | |
| SCHEMBL3354402 | 0.65 | GRM4 (0.44) | RAB9ANPC1KMT2AMEN1CASP3 | |
| SCHEMBL3360051 | 0.65 | RAB9A (0.41) | RAB9ANPC1KMT2AMEN1CASP3 | |
| SCHEMBL3355817 | 0.65 | ALDH1A1 (0.41) | RAB9ANPC1KMT2AMEN1CASP3 | |
| SCHEMBL4240553 | 0.64 | NPC1 (0.54) | RAB9ANPC1KMT2AMEN1CASP3 | |
| SCHEMBL28785190 | 0.64 | ACHE (0.52) | RAB9ANPC1KMT2AMEN1CASP3 | |
| SCHEMBL4242407 | 0.64 | RAB9A (0.61) | RAB9ANPC1KMT2AMEN1CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144756-A1 | NOVEL HETEROAROMATIC DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2010-06-10 | — | — | US | claimed |
| US-8524718-B2 | Heteroaromatic derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors | ADDEX PHARMA S.A. (CH) | 2013-09-03 | — | — | US | disclosed |
| US-20120329811-A1 | Heteroaromatic Derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors | BOLEA CHRISTELLE (CH) | 2012-12-27 | — | — | US | disclosed |
| US-20100144756-A1 | NOVEL HETEROAROMATIC DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144756-A1 | NOVEL HETEROAROMATIC DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | GRM3, GRM4, GRM2 | RAB9A 2813/4885NPC1 2378/4885KMT2A 1716/4885 |
| US-20120329811-A1 | Heteroaromatic Derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors | GRM3, GRM4, GRM1 | RAB9A 3067/4885NPC1 2504/4885KMT2A 1764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.